ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Selected studies evaluating efficacy of artemisinin combination therapies

Selected studies evaluating efficacy of artemisinin combination therapies
Reference Drug regimen Result Number patients Age Location Year
Ngasala BE et al[1] Artemether-lumefantrine High efficacy 359 Children Tanzania 2011
Achan J et al[2] Artemether-lumefantrine versus quinine Artemether-lumefantrine superior 175 Children Uganda 2009
Dorsey G et al[3] Artemether-lumefantrine verus artesunate-amodiaquine versus amodiaquine-sulfadoxine-pyrimethamine Artemether-lumefantrine superior 601 Children Uganda 2007
Zwang J et al[4] Artemether-lumefantrine versus artesunate-amodiaquine Artesunate-amodiaquine was followed by fewer recurrences 602 Children Uganda 2016
Toure O et al[5] Artemether-lumefantrine versus arterolane maleate-piperaquine phosphate Comparable efficacy and safety 859 Children Africa and India 2017
Thriemer K et al[6] Artemether-lumefantrine versus artesunate-azithromycin Equivalent cure rates 228 Adults and children Bangladesh 2010
Zwang J et al[7] Artesunate-amodiaquine versus non-ACT therapy Artesunate-amodiaquine superior to non-ACT therapy 11,700 Adults and children Multi-country 2009
Tahar R et al[8] Artesunate-amodiaquine versus atovaquone-proguanil versus artesunate-atovaquone-proguanil Equivalent efficacies by PCR; slower clearance with atovaquone-proguanil arm versus artesunate-atovaquone-proguanil 338 Children Cameroon 2014
Sirima S et al[9] Artesunate-mefloquine versus artemether-lumefantrine Comparable efficacy with similar rates of adverse events 945 Children Burkina Faso, Kenya, and Tanzania 2016
Smithuis F et al[10] Artesunate-mefloquine versus artesunate-amodiaquine versus dihydroartemisinin-piperaquine versus artemether-lumefantrine Artesunate-mefloquine greatest posttreatment suppression 808 Adults and children Myanmar 2010
Rueangweerayut R et al[11] Artesunate-mefloquine versus pyronaridine-artesunate Similar efficacies; longer parasite clearance times with pyronaridine-artesunate 1271 Adults and children Multi-country 2012
Sagara I et al[12] Either pyronaridine-artesunate or dihydroartemisinin-piperaquine versus either artesunate-amodiaquine or artemether-lumefantrine Pyronaridine-artesunate and dihydroartemisinin-piperaquine noninferior to artesunate-amodiaquine and artemether-lumefantrine 4710 Adults and children Burkina Faso, Guinea, and Mali 2018
Zani B et al[13] Dihydroartemisinin-piperaquine versus other ACTs

In Africa: Dihydroartemisinin-piperaquine reduces treatment failure compared with artemether-lumefantrine, (though both with PCR-adjusted failure rates <5%)

In Asia: Dihydroartemisinin-piperaquine as effective as artesunate-mefloquine		 16,382 Adults and children Multi-country 2014
Wanzira H et al[14] Dihydroartemisinin-piperaquine versus artemether-lumefantrine Dihydroartemisinin-piperaquine superior 312 Children Uganda 2014
Yeka et al[15] Dihydroartemisinin-piperaquine artemether-lumefantrine Regimens equivalent for treatment of uncomplicated Plasmodium falciparum malaria 599 Children Uganda 2019
Pryce et al[16] Pyronaridine-artesunate compared with alternative ACTs Pyronaridine-artesunate efficacious against uncomplicated P. falciparum malaria; treatment failure rate of <5% at days 28 and 42; may be at least as good as or better than other ACTs 5711 Adults and children Multicountry, Africa, and Asia 5 studies published up until October 2021
ACT: artemisinin combination therapy; PCR: polymerase chain reaction.
References:
  1. Ngasala BE, Malmberg M, Carlsson AM, et al. Efficacy and effectiveness of artemether-lumefantrine after initial and repeated treatment in children <5 years of age with acute uncomplicated Plasmodium falciparum malaria in rural Tanzania: a randomized trial. Clin Infect Dis 2011; 52:873.
  2. Achan J, Tibenderana JK, Kyabayinze D, et al. Effectiveness of quinine versus artemether-lumefantrine for treating uncomplicated falciparum malaria in Ugandan children: randomised trial. BMJ 2009; 339:b2763.
  3. Dorsey G, Staedke S, Clark TD, et al. Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial. JAMA 2007; 297:2210.
  4. Yeka A, Kigozi R, Conrad MD, et al. Artesunate/amodiaquine versus artemether/lumefantrine for the treatment of uncomplicated malaria in Uganda: A randomized trial. J Infect Dis 2016; 213:1134.
  5. Toure OA, Mwapasa V, Sagara I, et al. Assessment of efficacy and safety of arterolane maleate-piperaquine phosphate dispersible tablets in comparison with artemether-lumefantrine dispersible tablets in pediatric patients with acute uncomplicated Plasmodium falciparum malaria: A phase 3, randomized, multicenter trial in India and Africa. Clin Infect Dis 2017; 65:1711.
  6. Thriemer K, Starzengruber P, Khan WA, et al. Azithromycin combination therapy for the treatment of uncomplicated falciparum malaria in Bangladesh: an open-label randomized, controlled clinical trial. J Infect Dis 2010; 202:392.
  7. Zwang J, Olliaro P, Barennes H, et al. Efficacy of artesunate-amodiaquine for treating uncomplicated falciparum malaria in sub-Saharan Africa: a multi-centre analysis. Malar J 2009; 8:203.
  8. Tahar R, Almelli T, Debue C, et al. Randomized trial of artesunate-amodiaquine, atovaquone-proguanil, and artesunate-atovaquone-proguanil for the treatment of uncomplicated falciparum malaria in children. J Infect Dis 2014; 210:1962.
  9. Sirima SB, Ogutu B, Lusingu JPA, et al. Comparison of artesunate–mefloquine and artemether–lumefantrine fixed-dose combinations for treatment of uncomplicated Plasmodium falciparum malaria in children younger than 5 years in sub-Saharan Africa: a randomised, multicentre, phase 4 trial. Lancet 2016; 16:1123.
  10. Smithuis F, Kyaw MK, Phe O, et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial. Lancet Infect Dis 2010; 10:673.
  11. Rueangweerayut R, Phyo AP, Uthaisin C, et al. Pyronaridine-artesunate versus mefloquine plus artesunate for malaria. N Eng J Med 2012; 366:1298.
  12. West African Network for Clinical Trials of Antimalarial Drugs (WANECAM). Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial. Lancet 2018; 391:1378.
  13. Zani B, Gathu M, Donegan S, et al. Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database Syst Rev 2014; 1:CD010927.
  14. Wanzira H, Kakuru A, Arinaitwe E, et al. Longitudinal outcomes in a cohort of Ugandan children randomized to artemether-lumefantrine versus dihydroartemisinin-piperaquine for the treatment of malaria. Clin Infect Dis 2014; 59:509.
  15. Yeka A, Wallender E, Mulebeke R, et al. Comparative efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated malaria in Ugandan children. J Infect Dis 2019; 219:1112.
  16. Pryce J, Taylor M, Fox T, Hine P. Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database Syst Rev 2022; 6:CD006404.
Graphic 107437 Version 9.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟